NDAORALTABLET
Approved
Sep 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RENESE (polythiazide) by Pfizer is clinical pharmacology polythiazide renese (polythiazide) alone has demonstrated clinical effectiveness in lowering elevated blood pressure in patients without visible edema as well as in edematous hypertensive patients. Approved for pregnancy, just. First approved in 1961.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENESE (polythiazide) is a thiazide diuretic approved in 1961 that lowers elevated blood pressure by interfering with renal tubular electrolyte reabsorption. The combination formulation RENESE-R pairs polythiazide with reserpine, a sympathomimetic inhibitor, for enhanced antihypertensive efficacy. It is administered orally as a tablet for patients with hypertension, with or without edema.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal current spending, indicating a small, legacy-focused team managing end-of-life commercial operations.
Mechanism of Action
CLINICAL PHARMACOLOGY Polythiazide Renese (polythiazide) alone has demonstrated clinical effectiveness in lowering elevated blood pressure in patients without visible edema as well as in edematous hypertensive patients. Its mechanism of action results in an interference with the renal tubular…
Worked on RENESE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.